Science

Akhil Kapoor: Real-World Evidence for T-DM1 in HER2+ Metastatic Breast Cancer from India Published in Nature

Akhil Kapoor/X

Jun 1, 2025, 04:09

Akhil Kapoor: Real-World Evidence for T-DM1 in HER2+ Metastatic Breast Cancer from India Published in Nature

Akhil Kapoor, Professor, Medical Oncologist at TMH Varanasi, shared a post on LinkedIn:

“Real-world evidence for T-DM1 in HER2+ metastatic breast cancer from India published in the prestigious journal NATURE!
Retrospective study from Varanasi analyzed 70 patients with HER2-positive metastatic breast cancer treated between Jan 2020 – Dec 2022.

Efficacy highlights:

Median Progression-Free Survival (PFS): 6.1 months

Median Overall Survival (OS): 14.4 months

Objective Response Rate (ORR): 75.7%

Tolerability and Side Effects:

Most patients tolerated T-DM1 well

Common side effects:

Elevated liver enzymes (8.5%)

Thrombocytopenia (5.7%)

Anemia (4.2%)

Notable CNS activity:

T-DM1 showed promising results even in patients with brain metastases

Conclusion:

T-DM1 continues to be a valuable option in real-world treatment of HER2+ MBC, even outside clinical trials.

Title: Real-world data on trastuzumab emtansine (TDM1) efficacy and safety: Results of a single-centre retrospective study of HER2-positive metastatic breast cancer patients

Authors: Anuj Gupta, Bipinesh Sansar, Bal Krishna Mishra, Aqusa Khan, Arpita Singh,Arvind Upadhyay, Zachariah Chowdhury, Shashikant Patne, Mayank Tripathi2,Shreya Shukla, Satyendra Narayan Singh, Lincoln Pujari, Prashanth Giridhar, Ankita Rungta Kapoor, Arvind Suresh, Somnath Dey, Kunal Ranjan Vinayak, Neha Singh, Amit Kumar, Ankita Pal, Akhil Kapoor

You can read the Full Article on NATURE.

Akhil Kapoor: Real-World Evidence for T-DM1 in HER2+ Metastatic Breast Cancer from India Published in Nature

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

Science

OncoDaily

Science

Akhil Kapoor: Real-World Evidence for T-DM1 in HER2+ Metastatic Breast Cancer from India Published in Nature

“Real-world evidence for T-DM1 in HER2+ metastatic breast cancer from India published in the prestigious journal NATURE!
Retrospective study from Varanasi analyzed 70 patients with HER2-positive metastatic breast cancer treated between Jan 2020 – Dec 2022.

Efficacy highlights:

Median Progression-Free Survival (PFS): 6.1 months

Median Overall Survival (OS): 14.4 months

Objective Response Rate (ORR): 75.7%

Tolerability and Side Effects:

Most patients tolerated T-DM1 well

Common side effects:

Elevated liver enzymes (8.5%)

Thrombocytopenia (5.7%)

Anemia (4.2%)

Notable CNS activity:

T-DM1 showed promising results even in patients with brain metastases

Conclusion:

T-DM1 continues to be a valuable option in real-world treatment of HER2+ MBC, even outside clinical trials.

Science

OncoDaily

Science

Akhil Kapoor: Real-World Evidence for T-DM1 in HER2+ Metastatic Breast Cancer from India Published in Nature

“Real-world evidence for T-DM1 in HER2+ metastatic breast cancer from India published in the prestigious journal NATURE! Retrospective study from Varanasi analyzed 70 patients with HER2-positive metastatic breast cancer treated between Jan 2020 – Dec 2022.

Efficacy highlights:

Median Progression-Free Survival (PFS): 6.1 months

Median Overall Survival (OS): 14.4 months

Objective Response Rate (ORR): 75.7%

Tolerability and Side Effects:

Most patients tolerated T-DM1 well

Common side effects:

Elevated liver enzymes (8.5%)

Thrombocytopenia (5.7%)

Anemia (4.2%)

Notable CNS activity:

T-DM1 showed promising results even in patients with brain metastases

Conclusion:

T-DM1 continues to be a valuable option in real-world treatment of HER2+ MBC, even outside clinical trials.

“Real-world evidence for T-DM1 in HER2+ metastatic breast cancer from India published in the prestigious journal NATURE!
Retrospective study from Varanasi analyzed 70 patients with HER2-positive metastatic breast cancer treated between Jan 2020 – Dec 2022.